Harvard Medical School, Boston, Massachusetts, USA.
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):583-97. doi: 10.1016/j.ijrobp.2012.07.2352. Epub 2012 Sep 11.
In the enormity of the public health burden imposed by age-related macular degeneration (ARMD), much effort has been directed toward identifying effective and efficient treatments. Currently, anti-vascular endothelial growth factor (VEGF) injections have demonstrated considerably efficacy in treating neovascular ARMD, but patients require frequent treatment to fully benefit. Here, we review the rationale and evidence for radiation therapy of ARMD. The results of early photon external beam radiation therapy are included to provide a framework for the sequential discussion of evidence for the usage of stereotactic radiation therapy, proton therapy, and brachytherapy. The evidence suggests that these 3 modern modalities can provide a dose-dependent benefit in the treatment of ARMD. Most importantly, preliminary data suggest that all 3 can be used in conjunction with anti-VEGF therapeutics, thereby reducing the frequency of anti-VEGF injections required to maintain visual acuity.
在与年龄相关的黄斑变性(ARMD)相关的巨大公共卫生负担下,人们付出了大量努力来寻找有效且高效的治疗方法。目前,抗血管内皮生长因子(VEGF)注射已被证明在治疗新生血管性 ARMD 方面具有相当的疗效,但患者需要频繁治疗才能充分受益。在这里,我们回顾了 ARMD 放射治疗的基本原理和证据。早期光子外束放射治疗的结果包括在内,为顺序讨论立体定向放射治疗、质子治疗和近距离放射治疗的应用证据提供了一个框架。有证据表明,这 3 种现代方法可以为 ARMD 的治疗提供剂量依赖性益处。最重要的是,初步数据表明,所有 3 种方法都可以与抗 VEGF 治疗联合使用,从而减少维持视力所需的抗 VEGF 注射频率。